apatinib + camrelizumab + gemcitabine + capecitabine + docetaxel

This is a **combination regimen** consisting of five drugs: - **Apatinib**: an oral small-molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor 2 (VEGFR2), thereby inhibiting angiogenesis[3][5][7]. - **Camrelizumab**: a humanized monoclonal antibody programmed death-1 (PD-1) immune checkpoint inhibitor that enhances anti-tumor immune responses[5][7]. - **Gemcitabine**: a nucleoside analog that inhibits DNA synthesis, used as antineoplastic chemotherapy. - **Capecitabine**: an oral prodrug of 5-fluorouracil, inhibits DNA synthesis by interfering with thymidylate synthase, used as antimetabolite chemotherapy. - **Docetaxel**: a taxane-class chemotherapeutic agent that promotes and stabilizes microtubule assembly, inhibiting cell division, widely used in multiple solid tumors[2][4][6][8]. The combination aims to combine antiangiogenic, immunotherapeutic, and cytotoxic mechanisms to maximize anti-tumor activity, particularly in advanced or refractory cancers. This regimen is currently **investigational**, typically explored in clinical trials for advanced solid tumors such as hepatocellular carcinoma, breast cancer, and biliary tract cancers[1][3][5][7].